Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:CMPX NASDAQ:INBX NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$1.05-2.8%$0.83$0.55▼$1.66$135.63M1.11882,440 shs1.54 million shsCMPXCompass Therapeutics$4.28+0.9%$3.36$1.27▼$4.40$591.84M1.481.42 million shs1.58 million shsINBXInhibrx Biosciences$34.38+5.9%$27.64$10.81▼$37.53$497.99M0.51112,143 shs133,119 shsOCGNOcugen$1.60-6.4%$1.24$0.52▼$1.90$467.69M4.24.70 million shs10.28 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics0.00%+6.93%+28.60%+15.31%-25.00%CMPXCompass Therapeutics0.00%+14.59%+18.77%+45.21%+114.14%INBXInhibrx Biosciences0.00%-8.92%+17.99%+41.42%+107.61%OCGNOcugen0.00%-3.39%+59.81%+54.05%+73.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$1.05-2.8%$0.83$0.55▼$1.66$135.63M1.11882,440 shs1.54 million shsCMPXCompass Therapeutics$4.28+0.9%$3.36$1.27▼$4.40$591.84M1.481.42 million shs1.58 million shsINBXInhibrx Biosciences$34.38+5.9%$27.64$10.81▼$37.53$497.99M0.51112,143 shs133,119 shsOCGNOcugen$1.60-6.4%$1.24$0.52▼$1.90$467.69M4.24.70 million shs10.28 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics0.00%+6.93%+28.60%+15.31%-25.00%CMPXCompass Therapeutics0.00%+14.59%+18.77%+45.21%+114.14%INBXInhibrx Biosciences0.00%-8.92%+17.99%+41.42%+107.61%OCGNOcugen0.00%-3.39%+59.81%+54.05%+73.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 2.75Moderate Buy$6.25495.24% UpsideCMPXCompass Therapeutics 2.91Moderate Buy$13.10206.07% UpsideINBXInhibrx Biosciences 1.50ReduceN/AN/AOCGNOcugen 2.50Moderate Buy$6.00275.00% UpsideCurrent Analyst Ratings BreakdownLatest ATOS, OCGN, INBX, and CMPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ATOSAtossa GeneticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CMPXCompass TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025INBXInhibrx BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025OCGNOcugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/6/2025CMPXCompass TherapeuticsCompass PointSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.0010/6/2025CMPXCompass TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.009/27/2025ATOSAtossa GeneticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CMPXCompass TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025INBXInhibrx BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025OCGNOcugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/22/2025ATOSAtossa GeneticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.50 ➝ $7.75(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$0.57 per shareN/ACMPXCompass Therapeutics$850K696.28N/AN/A$0.91 per share4.70INBXInhibrx Biosciences$1.40M355.71$122.79 per share0.28$9.23 per share3.72OCGNOcugen$4.75M98.38N/AN/A$0.10 per share16.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$25.50M-$0.23N/AN/AN/AN/A-40.28%-37.10%11/11/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.45N/AN/AN/AN/A-53.11%-46.14%11/11/2025 (Estimated)INBXInhibrx Biosciences$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)OCGNOcugen-$54.05M-$0.20N/AN/AN/A-1,197.71%-255.25%-86.79%11/13/2025 (Estimated)Latest ATOS, OCGN, INBX, and CMPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025INBXInhibrx Biosciences-$2.92-$1.85+$1.07-$1.85N/A$1.30 million8/12/2025Q2 2025ATOSAtossa Genetics-$0.06-$0.07-$0.01-$0.07N/AN/A8/11/2025Q2 2025CMPXCompass Therapeutics-$0.13-$0.14-$0.01-$0.14N/AN/A8/1/2025Q2 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A9.179.17CMPXCompass TherapeuticsN/A7.667.66INBXInhibrx Biosciences1.454.984.98OCGNOcugen9.181.831.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%CMPXCompass Therapeutics68.43%INBXInhibrx Biosciences82.46%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipATOSAtossa Genetics8.70%CMPXCompass Therapeutics29.80%INBXInhibrx Biosciences17.09%OCGNOcugen4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics8129.17 million117.93 millionOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableINBXInhibrx Biosciences16614.49 millionN/AOptionableOCGNOcugen80292.31 million279.77 millionOptionableATOS, OCGN, INBX, and CMPX HeadlinesRecent News About These CompaniesOcugen (NASDAQ:OCGN) Shares Down 7.4% - Should You Sell?October 11 at 12:36 PM | marketbeat.comWeiss Ratings Reaffirms Sell (E+) Rating for Ocugen (NASDAQ:OCGN)October 10 at 8:22 AM | marketbeat.comOcugen to Highlight Gene Therapy Pipeline at Key Industry and Investor ConferencesOctober 6, 2025 | msn.comOcugen (NASDAQ:OCGN) Hits New 52-Week High - Here's WhyOctober 3, 2025 | marketbeat.comOcugen to Present at Industry and Investor Conferences in October 2025October 2, 2025 | markets.businessinsider.comOcugen to Present at Major Biotechnology Conferences Focused on Advancements in Gene Therapies for Blindness DiseasesOctober 2, 2025 | quiverquant.comQTraders Buy High Volume of Ocugen Call Options (NASDAQ:OCGN)October 1, 2025 | marketbeat.comGoldman Sachs Group Inc. Lowers Holdings in Ocugen, Inc. $OCGNSeptember 27, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Reaches New 52-Week High - Time to Buy?September 24, 2025 | marketbeat.comOcugen: A Retinal Disease Juggernaut In The MakingSeptember 23, 2025 | seekingalpha.comOcugen (NASDAQ:OCGN) Earns Buy Rating from Chardan CapitalSeptember 20, 2025 | marketbeat.com200,100 Shares in Ocugen, Inc. $OCGN Purchased by Procyon Advisors LLCSeptember 20, 2025 | marketbeat.comOcugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in KoreaSeptember 20, 2025 | msn.comOcugen (NASDAQ:OCGN) Upgraded by Wall Street Zen to Hold RatingSeptember 20, 2025 | marketbeat.comForecasting The Future: 4 Analyst Projections For OcugenSeptember 19, 2025 | benzinga.comOcugen (OCGN): Evaluating Valuation Following Exclusive Korean Licensing Deal for Gene Therapy OCU400September 18, 2025 | finance.yahoo.comWhy Ocugen (OCGN) Is Up 16.5% After Licensing OCU400 Gene Therapy Rights to KwangdongSeptember 16, 2025 | finance.yahoo.comOcugen Signs Exclusive License Agreement with KwangdongSeptember 16, 2025 | tipranks.comOcugen executes licensing agreement with Kwangdong PharmaceuticalSeptember 15, 2025 | msn.comOcugen, Inc. Announces Licensing Agreement with Kwangdong Pharmaceutical for OCU400, Potentially Worth Up to $187.5 MillionSeptember 15, 2025 | quiverquant.comQOcugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in KoreaSeptember 15, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 20252 Defense Stocks Riding 2025’s Massive Momentum WaveBy Leo Miller | October 7, 2025ATOS, OCGN, INBX, and CMPX Company DescriptionsAtossa Genetics NASDAQ:ATOS$1.05 -0.03 (-2.78%) Closing price 04:00 PM EasternExtended Trading$1.10 +0.04 (+4.29%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Compass Therapeutics NASDAQ:CMPX$4.28 +0.04 (+0.94%) Closing price 04:00 PM EasternExtended Trading$4.32 +0.04 (+1.05%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Inhibrx Biosciences NASDAQ:INBX$34.38 +1.91 (+5.88%) Closing price 04:00 PM EasternExtended Trading$34.34 -0.04 (-0.12%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Ocugen NASDAQ:OCGN$1.60 -0.11 (-6.43%) Closing price 04:00 PM EasternExtended Trading$1.60 0.00 (0.00%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
